25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RLMD (Relmada) Stock Analysis
Buy, Hold or Sell?

Let's analyze Relmada together

I guess you are interested in Relmada Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Relmada’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Relmada’s Price Targets

I'm going to help you getting a better view of Relmada Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Relmada Therapeutics Inc

I send you an email if I find something interesting about Relmada Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Relmada (30 sec.)










1.2. What can you expect buying and holding a share of Relmada? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.68
Expected worth in 1 year
$-0.82
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.49
Return On Investment
-237.2%

For what price can you sell your share?

Current Price per Share
$0.63
Expected price per share
$0.2675 - $1.88
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Relmada (5 min.)




Live pricePrice per Share (EOD)
$0.63
Intrinsic Value Per Share
$-21.29 - $-7.90
Total Value Per Share
$-20.62 - $-7.22

2.2. Growth of Relmada (5 min.)




Is Relmada growing?

Current yearPrevious yearGrowGrow %
How rich?$22.4m$92.3m-$50.5m-121.1%

How much money is Relmada making?

Current yearPrevious yearGrowGrow %
Making money-$18.9m-$23.5m$4.6m24.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Relmada (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#502 / 881

Most Revenue
#742 / 881

Most Profit
#636 / 881

Most Efficient
#362 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Relmada?

Welcome investor! Relmada's management wants to use your money to grow the business. In return you get a share of Relmada.

First you should know what it really means to hold a share of Relmada. And how you can make/lose money.

Speculation

The Price per Share of Relmada is $0.63. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Relmada.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Relmada, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.68. Based on the TTM, the Book Value Change Per Share is $-0.37 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Relmada.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.53-84.0%-0.57-90.5%-0.71-112.7%-0.79-125.0%-0.80-126.2%-0.43-68.9%
Usd Book Value Change Per Share-0.39-62.6%-0.37-59.3%-0.40-63.9%-0.47-74.9%-0.14-21.7%0.022.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.39-62.6%-0.37-59.3%-0.40-63.9%-0.47-74.9%-0.14-21.7%0.022.4%
Usd Price Per Share0.27-1.76-3.56-6.92-17.02-11.27-
Price to Earnings Ratio-0.13--0.75--1.27--1.77--6.26--7.78-
Price-to-Total Gains Ratio-0.69--4.83--8.92--12.61-11.64-162.72-
Price to Book Ratio0.40-1.19-1.37-1.85-4.87-11.39-
Price-to-Total Gains Ratio-0.69--4.83--8.92--12.61-11.64-162.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.63
Number of shares1587
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.37-0.14
Usd Total Gains Per Share-0.37-0.14
Gains per Quarter (1587 shares)-592.95-216.88
Gains per Year (1587 shares)-2,371.82-867.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2372-23820-868-878
20-4744-47540-1735-1746
30-7115-71260-2603-2614
40-9487-94980-3470-3482
50-11859-118700-4338-4350
60-14231-142420-5205-5218
70-16603-166140-6073-6086
80-18975-189860-6940-6954
90-21346-213580-7808-7822
100-23718-237300-8675-8690

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%4.049.00.07.5%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%10.030.00.025.0%13.037.03.024.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.053.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%10.030.00.025.0%13.037.03.024.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Relmada Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.394-0.374-5%-0.402+2%-0.472+20%-0.137-65%0.015-2723%
Book Value Per Share--0.6761.258-46%2.783-76%2.927-77%3.322-80%1.884-64%
Current Ratio--5.2876.017-12%9.794-46%9.111-42%13.203-60%10.913-52%
Debt To Asset Ratio--0.1890.173+9%0.109+74%0.124+53%0.111+71%0.496-62%
Debt To Equity Ratio--0.2330.212+10%0.124+89%0.144+62%0.129+81%0.642-64%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--30783838.00099172866.000-69%208507935.000-85%324603659.167-91%672574652.200-95%434883226.271-93%
Eps---0.529-0.570+8%-0.710+34%-0.787+49%-0.795+50%-0.434-18%
Ev To Ebitda Ratio---0.422-1.226+190%-2.140+406%-2.529+499%-7.029+1564%-8.305+1866%
Free Cash Flow Per Share---0.544-0.428-21%-0.363-33%-0.517-5%-0.514-5%-0.296-46%
Free Cash Flow To Equity Per Share---0.544-0.430-21%-0.362-33%-0.479-12%-0.125-77%-198.654+36395%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0040%
Intrinsic Value_10Y_max---7.899----------
Intrinsic Value_10Y_min---21.292----------
Intrinsic Value_1Y_max---1.128----------
Intrinsic Value_1Y_min---2.092----------
Intrinsic Value_3Y_max---3.132----------
Intrinsic Value_3Y_min---6.359----------
Intrinsic Value_5Y_max---4.828----------
Intrinsic Value_5Y_min---10.673----------
Market Cap20910708.000+57%8961732.00058334237.000-85%118245075.000-92%229685872.000-96%564970819.400-98%374214462.271-98%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio0.932+57%0.3991.191-66%1.369-71%1.854-78%4.869-92%11.391-96%
Pe Ratio-0.298-133%-0.128-0.749+487%-1.268+894%-1.774+1290%-6.265+4810%-7.783+6000%
Price Per Share0.630+57%0.2701.758-85%3.563-92%6.920-96%17.022-98%11.274-98%
Price To Free Cash Flow Ratio-0.289-133%-0.124-1.026+728%-2.497+1914%-2.897+2236%-11.679+9318%-13.242+10578%
Price To Total Gains Ratio-1.598-133%-0.685-4.825+604%-8.925+1203%-12.607+1740%11.635-106%162.715-100%
Quick Ratio--10.12611.558-12%18.530-45%16.937-40%24.631-59%19.049-47%
Return On Assets---0.634-0.420-34%-0.231-64%-0.287-55%-0.255-60%-0.379-40%
Return On Equity---0.782-0.513-34%-0.261-67%-0.335-57%-0.295-62%-0.566-28%
Total Gains Per Share---0.394-0.374-5%-0.402+2%-0.472+20%-0.137-65%0.015-2723%
Usd Book Value--22440491.00041769815.500-46%92366490.750-76%97137242.083-77%110251138.900-80%62528612.400-64%
Usd Book Value Change Per Share---0.394-0.374-5%-0.402+2%-0.472+20%-0.137-65%0.015-2723%
Usd Book Value Per Share--0.6761.258-46%2.783-76%2.927-77%3.322-80%1.884-64%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--30783838.00099172866.000-69%208507935.000-85%324603659.167-91%672574652.200-95%434883226.271-93%
Usd Eps---0.529-0.570+8%-0.710+34%-0.787+49%-0.795+50%-0.434-18%
Usd Free Cash Flow---18067033.000-14196520.750-21%-12047715.000-33%-17154492.583-5%-17077054.350-5%-9815166.700-46%
Usd Free Cash Flow Per Share---0.544-0.428-21%-0.363-33%-0.517-5%-0.514-5%-0.296-46%
Usd Free Cash Flow To Equity Per Share---0.544-0.430-21%-0.362-33%-0.479-12%-0.125-77%-198.654+36395%
Usd Market Cap20910708.000+57%8961732.00058334237.000-85%118245075.000-92%229685872.000-96%564970819.400-98%374214462.271-98%
Usd Price Per Share0.630+57%0.2701.758-85%3.563-92%6.920-96%17.022-98%11.274-98%
Usd Profit---17559000.000-18927500.000+8%-23574500.000+34%-26135666.667+49%-26395400.000+50%-14406892.150-18%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---0.394-0.374-5%-0.402+2%-0.472+20%-0.137-65%0.015-2723%
 EOD+5 -3MRQTTM+7 -25YOY+11 -213Y+11 -215Y+6 -2610Y+7 -26

3.3 Fundamental Score

Let's check the fundamental score of Relmada Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.298
Price to Book Ratio (EOD)Between0-10.932
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.126
Current Ratio (MRQ)Greater than15.287
Debt to Asset Ratio (MRQ)Less than10.189
Debt to Equity Ratio (MRQ)Less than10.233
Return on Equity (MRQ)Greater than0.15-0.782
Return on Assets (MRQ)Greater than0.05-0.634
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Relmada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.641
Ma 20Greater thanMa 500.685
Ma 50Greater thanMa 1000.586
Ma 100Greater thanMa 2000.439
OpenGreater thanClose0.620
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Relmada Therapeutics Inc

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Fundamental data was last updated by Penke on 2025-06-20 14:30:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Relmada earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Relmada to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Relmada Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--139.0%+139.0%
YOY--194.4%+194.4%
3Y--248.5%+248.5%
5Y--343.3%+343.3%
10Y--488.9%+488.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Relmada is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Relmada to theΒ Biotechnology industry mean.
  • -63.4% Return on Assets means thatΒ Relmada generatedΒ $-0.63 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Relmada Therapeutics Inc:

  • The MRQ is -63.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-63.4%TTM-42.0%-21.4%
TTM-42.0%YOY-23.1%-18.9%
TTM-42.0%5Y-25.5%-16.6%
5Y-25.5%10Y-37.9%+12.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-63.4%-11.6%-51.8%
TTM-42.0%-11.7%-30.3%
YOY-23.1%-11.4%-11.7%
3Y-28.7%-11.9%-16.8%
5Y-25.5%-12.1%-13.4%
10Y-37.9%-13.8%-24.1%
4.3.1.3. Return on Equity

Shows how efficient Relmada is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Relmada to theΒ Biotechnology industry mean.
  • -78.2% Return on Equity means Relmada generated $-0.78Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Relmada Therapeutics Inc:

  • The MRQ is -78.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -51.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-78.2%TTM-51.3%-26.9%
TTM-51.3%YOY-26.1%-25.2%
TTM-51.3%5Y-29.5%-21.9%
5Y-29.5%10Y-56.6%+27.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-78.2%-13.5%-64.7%
TTM-51.3%-15.0%-36.3%
YOY-26.1%-14.5%-11.6%
3Y-33.5%-16.9%-16.6%
5Y-29.5%-17.9%-11.6%
10Y-56.6%-19.9%-36.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Relmada Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Relmada is operatingΒ .

  • Measures how much profit Relmada makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Relmada to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Relmada Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.7%+249.7%
YOY--208.4%+208.4%
3Y--221.7%+221.7%
5Y--344.1%+344.1%
10Y--470.4%+470.4%
4.3.2.2. Operating Ratio

Measures how efficient Relmada is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM-2.680-2.680
YOY-3.080-3.080
3Y-3.621-3.621
5Y-4.734-4.734
10Y-6.546-6.546
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Relmada Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Relmada is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.29Β means the company has $5.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 5.287. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.017. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.287TTM6.017-0.730
TTM6.017YOY9.794-3.777
TTM6.0175Y13.203-7.187
5Y13.20310Y10.913+2.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2873.659+1.628
TTM6.0173.834+2.183
YOY9.7944.141+5.653
3Y9.1114.661+4.450
5Y13.2035.756+7.447
10Y10.9136.151+4.762
4.4.3.2. Quick Ratio

Measures if Relmada is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Relmada to theΒ Biotechnology industry mean.
  • A Quick Ratio of 10.13Β means the company can pay off $10.13 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 10.126. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.558. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.126TTM11.558-1.432
TTM11.558YOY18.530-6.972
TTM11.5585Y24.631-13.073
5Y24.63110Y19.049+5.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.1262.799+7.327
TTM11.5583.143+8.415
YOY18.5303.794+14.736
3Y16.9374.307+12.630
5Y24.6315.707+18.924
10Y19.0496.457+12.592
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Relmada Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of RelmadaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Relmada to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19Β means that Relmada assets areΒ financed with 18.9% credit (debt) and the remaining percentage (100% - 18.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.189. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.173. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.189TTM0.173+0.016
TTM0.173YOY0.109+0.064
TTM0.1735Y0.111+0.062
5Y0.11110Y0.496-0.385
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1890.324-0.135
TTM0.1730.347-0.174
YOY0.1090.329-0.220
3Y0.1240.340-0.216
5Y0.1110.349-0.238
10Y0.4960.379+0.117
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Relmada is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Relmada to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 23.3% means that company has $0.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.233. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.212. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.212+0.021
TTM0.212YOY0.124+0.089
TTM0.2125Y0.129+0.083
5Y0.12910Y0.642-0.513
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2330.379-0.146
TTM0.2120.435-0.223
YOY0.1240.412-0.288
3Y0.1440.446-0.302
5Y0.1290.460-0.331
10Y0.6420.509+0.133
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Relmada generates.

  • Above 15 is considered overpriced butΒ always compareΒ Relmada to theΒ Biotechnology industry mean.
  • A PE ratio of -0.13 means the investor is paying $-0.13Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Relmada Therapeutics Inc:

  • The EOD is -0.298. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.128. Based on the earnings, the company is expensive. -2
  • The TTM is -0.749. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.298MRQ-0.128-0.170
MRQ-0.128TTM-0.749+0.622
TTM-0.749YOY-1.268+0.518
TTM-0.7495Y-6.265+5.516
5Y-6.26510Y-7.783+1.518
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.298-2.282+1.984
MRQ-0.128-2.062+1.934
TTM-0.749-2.541+1.792
YOY-1.268-3.722+2.454
3Y-1.774-3.754+1.980
5Y-6.265-6.100-0.165
10Y-7.783-6.653-1.130
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Relmada Therapeutics Inc:

  • The EOD is -0.289. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.124. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.026. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.289MRQ-0.124-0.165
MRQ-0.124TTM-1.026+0.902
TTM-1.026YOY-2.497+1.471
TTM-1.0265Y-11.679+10.653
5Y-11.67910Y-13.242+1.563
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.289-3.101+2.812
MRQ-0.124-2.689+2.565
TTM-1.026-3.594+2.568
YOY-2.497-4.363+1.866
3Y-2.897-5.065+2.168
5Y-11.679-8.478-3.201
10Y-13.242-9.273-3.969
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Relmada is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.40 means the investor is paying $0.40Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Relmada Therapeutics Inc:

  • The EOD is 0.932. Based on the equity, the company is cheap. +2
  • The MRQ is 0.399. Based on the equity, the company is cheap. +2
  • The TTM is 1.191. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.932MRQ0.399+0.532
MRQ0.399TTM1.191-0.791
TTM1.191YOY1.369-0.178
TTM1.1915Y4.869-3.679
5Y4.86910Y11.391-6.522
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9321.932-1.000
MRQ0.3991.848-1.449
TTM1.1912.119-0.928
YOY1.3692.469-1.100
3Y1.8542.526-0.672
5Y4.8693.667+1.202
10Y11.3914.351+7.040
4.6.2. Total Gains per Share

2.4. Latest News of Relmada Therapeutics Inc

Does Relmada Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Relmada Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-17
13:28
Relmada Therapeutics Hires Raj S. Pruthi As Chief Medical Officer-UrologyRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Relmada Therapeutics Inc.

4.8.1. Institutions holding Relmada Therapeutics Inc

Institutions are holding 33.389% of the shares of Relmada Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Acadian Asset Management LLC3.69950.0009122792812279280
2025-03-31Vanguard Group Inc3.639701208075-48630-3.8696
2025-03-31BlackRock Inc1.7080566905-26421-4.453
2025-03-31Palo Alto Investors, LLC1.49180.025549514600
2025-03-31Geode Capital Management, LLC0.90950301883-955-0.3154
2025-03-31Two Sigma Advisers, LLC0.86770.00022880008910044.7964
2025-03-31AdvisorShares Investments, LLC0.83310.01482765146644631.6307
2025-03-31Deutsche Bank AG0.6774022484600
2024-12-31UBS Group AG0.648202151408875570.2259
2025-03-31Two Sigma Investments LLC0.51380.00011705444296533.6772
2025-03-31Parsons Capital Management Inc0.49210.002416333600
2025-03-31RBF LLC0.49190.002716326100
2025-03-31Renaissance Technologies Corp0.37390.0001124100-40413-24.5652
2025-03-31Goldman Sachs Group Inc0.364101208521208520
2025-03-31State Street Corp0.3216010673500
2025-03-31We Are One Seven, LLC0.30130.001110000000
2025-03-31Northern Trust Corp0.1795059571-24711-29.3194
2025-03-31HRT FINANCIAL LLC0.15680.000152043520430
2025-03-31apricus wealth, LLC0.14750.00794896200
2025-03-31Franklin Resources Inc0.1289042797-1259354-96.7134
Total 17.94630.05585956638+287605+4.8%

4.9.2. Funds holding Relmada Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.06540.000135362500
2025-05-30AdvisorShares Psychedelics ETF0.98372.465632651400
2025-04-30Fidelity Extended Market Index0.480.0001159305-1523-0.947
2025-04-30Goldman Sachs Absolute Ret Trckr Instl0.19990.000366365-31500-32.1872
2025-04-30Fidelity Total Market Index0.168905607100
2025-05-31iShares Micro-Cap ETF0.14750.00474894400
2025-03-31Extended Equity Market Fund K0.14340.0001476081460.3076
2025-04-30Fidelity Series Total Market Index0.117103885400
2025-03-04Acadian Global Small-Cap Equity CIT Cl A0.10920.00223623000
2025-03-31NT Ext Equity Mkt Idx Fd - L0.10650.00013535100
2025-03-31Northern Trust Extended Eq Market Idx0.10650.00013535100
2025-04-30Spartan Extended Market Index Pool F0.08690.00012885415235.5724
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.06140.00012036800
2024-12-31Vanguard Instl Ttl Stck Mkt Idx Tr0.060902022300
2025-04-30Spartan Total Market Index Pool G0.049301636412548.2991
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04780.000115855-289-1.7901
2025-04-30Vanguard U.S. Eq Idx Β£ Acc0.031501045200
2025-03-31U.S. Equity Market Fund F0.0304010101-15-0.1483
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.02560.00018490670.7954
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.02540.0002842384230
Total 4.04732.47391343348-21914-1.6%

5.3. Insider Transactions

Insiders are holding 17.025% of the shares of Relmada Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-20Maged ShenoudaBUY600000.52
2025-05-19Maged ShenoudaBUY900000.49
2025-05-16Chuck EnceBUY2289610.45
2025-05-16Maged ShenoudaBUY500000.44
2025-05-16Paul Edward KellyBUY2000000.43
2024-09-11Maged ShenoudaBUY241202.95
2024-09-11Sergio TraversaBUY514072.99
2024-09-09Charles J CasamentoBUY130002.56
2024-09-09Maged ShenoudaBUY81942.55
2024-09-09Sergio TraversaBUY555792.71
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets27,679
Total Liabilities5,239
Total Stockholder Equity22,440
 As reported
Total Liabilities 5,239
Total Stockholder Equity+ 22,440
Total Assets = 27,679

Assets

Total Assets27,679
Total Current Assets27,657
Long-term Assets22
Total Current Assets
Cash And Cash Equivalents 1,150
Short-term Investments 25,911
Other Current Assets 596
Total Current Assets  (as reported)27,657
Total Current Assets  (calculated)27,657
+/-0
Long-term Assets
Long-term Assets Other 22
Long-term Assets  (as reported)22
Long-term Assets  (calculated)22
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,231
Long-term Liabilities8
Total Stockholder Equity22,440
Total Current Liabilities
Accounts payable 1,265
Other Current Liabilities 2,701
Total Current Liabilities  (as reported)5,231
Total Current Liabilities  (calculated)3,966
+/- 1,265
Long-term Liabilities
Long-term Liabilities  (as reported)8
Long-term Liabilities  (calculated)0
+/- 8
Total Stockholder Equity
Common Stock33
Retained Earnings -658,442
Other Stockholders Equity 680,849
Total Stockholder Equity (as reported)22,440
Total Stockholder Equity (calculated)22,440
+/-0
Other
Capital Stock33
Cash and Short Term Investments 27,061
Common Stock Shares Outstanding 30,409
Liabilities and Stockholders Equity 27,679
Net Debt -1,150
Net Invested Capital 22,440
Net Working Capital 22,426



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
0
0
18
0
10
10
5
20
12
10
25,764
27,847
32,792
27,850
24,393
20,485
16,604
12,718
10,244
7,922
6,225
4,170
2,837
5,614
6,574
4,796
3,048
1,556
3,299
2,604
10,220
8,514
117,136
115,421
134,559
125,599
118,186
103,867
110,769
90,934
223,326
225,808
215,772
187,122
152,905
135,566
122,038
109,149
97,552
84,408
71,028
55,725
45,818
27,679
27,67945,81855,72571,02884,40897,552109,149122,038135,566152,905187,122215,772225,808223,32690,934110,769103,867118,186125,599134,559115,421117,1368,51410,2202,6043,2991,5563,0484,7966,5745,6142,8374,1706,2257,92210,24412,71816,60420,48524,39327,85032,79227,84725,7641012205101001800
   > Total Current Assets 
0
0
18
0
10
10
3
18
11
9
25,743
27,818
32,756
27,814
23,968
20,050
15,656
11,775
9,298
6,972
5,296
3,244
2,475
5,265
6,242
4,481
2,738
1,270
3,032
2,330
9,984
8,298
116,940
115,245
134,405
125,465
118,074
103,776
110,700
90,887
223,298
225,779
215,737
187,106
152,870
135,532
122,004
109,101
97,509
84,365
70,975
55,703
45,796
27,657
27,65745,79655,70370,97584,36597,509109,101122,004135,532152,870187,106215,737225,779223,29890,887110,700103,776118,074125,465134,405115,245116,9408,2989,9842,3303,0321,2702,7384,4816,2425,2652,4753,2445,2966,9729,29811,77515,65620,05023,96827,81432,75627,81825,743911183101001800
       Cash And Cash Equivalents 
0
0
9
0
8
8
1
15
6
3
25,564
27,391
31,419
26,956
22,470
19,165
15,128
11,349
8,500
6,222
4,714
2,757
1,711
4,685
5,940
4,258
2,239
887
2,427
2,054
9,217
7,850
36,279
12,226
13,824
7,545
2,495
3,804
4,669
11,449
44,443
44,934
37,261
42,524
5,396
28,894
14,469
6,699
4,092
1,335
2,086
1,484
3,857
1,150
1,1503,8571,4842,0861,3354,0926,69914,46928,8945,39642,52437,26144,93444,44311,4494,6693,8042,4957,54513,82412,22636,2797,8509,2172,0542,4278872,2394,2585,9404,6851,7112,7574,7146,2228,50011,34915,12819,16522,47026,95631,41927,39125,56436151880900
       Short-term Investments 
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80,165
102,691
120,264
115,594
114,596
98,900
104,399
76,638
167,466
175,716
174,694
141,628
142,927
103,548
104,060
99,569
92,232
82,278
68,351
52,634
41,052
25,911
25,91141,05252,63468,35182,27892,23299,569104,060103,548142,927141,628174,694175,716167,46676,638104,39998,900114,596115,594120,264102,69180,16500000000000000000000000000400000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
82
0
0
0
263
234
2
0
292
211
62
63
72
66
67
69
247
72
73
82
76
78
79
81
83
85
86
65
42
0
512
0
0
0
0
0
0
0
0
0
0000000005120426586858381797876827372247696766726362211292022342630008200000000000000
       Other Current Assets 
0
0
3
0
0
0
0
0
0
0
356
428
1,337
858
1,498
885
528
427
810
516
579
487
472
369
240
160
427
317
538
208
521
377
424
246
241
2,249
903
991
1,549
2,715
11,302
5,064
3,740
2,954
4,035
3,090
3,475
2,834
1,185
752
538
1,585
886
596
5968861,5855387521,1852,8343,4753,0904,0352,9543,7405,06411,3022,7151,5499919032,2492412464243775212085383174271602403694724875795168104275288851,4988581,3374283560000000300
   > Long-term Assets 
0
0
0
0
0
-2
2
2
1
1
22
29
36
35
425
434
949
942
946
951
930
927
362
348
332
315
310
286
267
273
235
216
196
176
155
134
113
91
69
47
28
28
35
16
35
35
35
48
43
43
54
22
22
22
2222225443434835353516352828476991113134155176196216235273267286310315332348362927930951946942949434425353629221122-200000
       Property Plant Equipment 
0
0
0
0
0
0
2
2
1
1
10
17
24
23
24
22
536
530
531
536
515
512
2
4
4
3
12
11
9
8
7
6
5
4
3
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000123456789111234425125155365315305362224232417101122000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
338
322
306
290
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000002903063223380000000000000000000000
       Other Assets 
0
0
0
0
0
2
0
0
0
0
12
12
12
401
0
412
413
413
415
415
415
414
360
345
328
311
298
275
258
0
228
0
25
172
152
132
111
90
69
47
28
28
35
16
35
0
35
0
0
0
0
0
0
0
00000003503516352828476990111132152172250228025827529831132834536041441541541541341341204011212120000200000
> Total Liabilities 
0
0
7
0
12
12
26
34
40
41
26,773
48,570
28,199
25,356
15,583
6,649
4,840
2,513
3,202
2,348
1,550
1,368
1,377
4,149
5,853
7,112
8,561
10,296
1,864
2,130
2,606
2,537
1,458
2,261
2,326
3,389
12,603
12,719
13,917
18,247
15,061
15,409
18,921
20,777
12,469
10,097
10,702
8,422
12,195
12,362
9,537
8,099
10,296
5,239
5,23910,2968,0999,53712,36212,1958,42210,70210,09712,46920,77718,92115,40915,06118,24713,91712,71912,6033,3892,3262,2611,4582,5372,6062,1301,86410,2968,5617,1125,8534,1491,3771,3681,5502,3483,2022,5134,8406,64915,58325,35628,19948,57026,7734140342612120700
   > Total Current Liabilities 
0
0
7
0
12
12
26
34
40
41
26,773
48,470
28,099
25,256
15,583
6,649
4,785
2,404
3,061
2,214
1,413
1,229
1,377
3,470
4,575
5,535
5,905
7,103
1,864
2,130
2,606
2,537
1,458
2,261
2,326
3,389
12,603
12,719
13,917
18,247
15,061
15,409
18,921
20,777
12,469
10,097
10,702
8,422
12,195
12,362
9,537
8,087
10,291
5,231
5,23110,2918,0879,53712,36212,1958,42210,70210,09712,46920,77718,92115,40915,06118,24713,91712,71912,6033,3892,3262,2611,4582,5372,6062,1301,8647,1035,9055,5354,5753,4701,3771,2291,4132,2143,0612,4044,7856,64915,58325,25628,09948,47026,7734140342612120700
       Short-term Debt 
0
0
0
0
0
0
0
844
840
60
58
148
38
264
264
176
89
614
274
164
110
28
277
194
111
28
285
200
115
29
364
256
110
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000110110256364291152002852811119427728110164274614891762642643814858608408440000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
634
307
277
873
1,389
1,604
2,942
0
0
29
364
256
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000011025636429002,9421,6041,38987327730763400000000000000000000
       Accounts payable 
0
0
7
0
12
12
26
34
40
41
746
625
970
390
835
1,150
1,688
744
1,260
672
307
335
530
351
286
1,092
765
1,019
359
1,080
359
1,267
523
1,103
965
729
8,346
8,083
10,456
12,709
11,193
10,670
7,540
10,426
5,262
4,422
4,854
2,857
3,506
5,189
4,175
2,346
4,131
1,265
1,2654,1312,3464,1755,1893,5062,8574,8544,4225,26210,4267,54010,67011,19312,70910,4568,0838,3467299651,1035231,2673591,0803591,0197651,0922863515303353076721,2607441,6881,1508353909706257464140342612120700
       Other Current Liabilities 
0
0
0
0
0
0
0
-844
0
0
25,969
47,697
27,091
24,865
14,484
5,323
3,009
1,660
1,527
1,377
996
866
570
2,925
4,178
4,416
4,854
5,884
1,391
1,021
1,883
1,014
825
1,158
1,361
2,661
4,257
4,637
3,461
5,539
3,868
4,739
11,381
10,351
7,207
5,675
5,849
5,565
8,689
7,173
5,362
5,741
6,161
2,701
2,7016,1615,7415,3627,1738,6895,5655,8495,6757,20710,35111,3814,7393,8685,5393,4614,6374,2572,6611,3611,1588251,0141,8831,0211,3915,8844,8544,4164,1782,9255708669961,3771,5271,6603,0095,32314,48424,86527,09147,69725,96900-8440000000
   > Long-term Liabilities 
0
0
7
0
0
12
26
34
40
41
100
100
100
100
1,099
1,326
55
109
141
135
137
139
806
679
1,278
1,576
2,656
3,193
474
3,193
1,289
0
633
1,103
965
729
8,346
8,083
10,456
12,709
11,193
10,670
7,540
10,426
5,262
4,422
0
0
0
0
0
13
4
8
8413000004,4225,26210,4267,54010,67011,19312,70910,4568,0838,3467299651,10363301,2893,1934743,1932,6561,5761,278679806139137135141109551,3261,099100100100100414034261200700
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
679
1,278
1,576
2,656
3,193
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000003,1932,6561,5761,27867900000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
100
100
100
0
0
0
55
109
141
134
137
139
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000139137134141109550001001001000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000550000000000000000
> Total Stockholder Equity
0
0
11
0
-2
-2
-21
-14
-28
-31
-1,109
-20,722
4,593
2,494
8,810
13,836
11,764
10,205
7,042
5,574
4,675
2,802
1,460
1,465
721
-2,316
-5,513
-8,740
1,435
474
7,613
5,977
115,678
113,160
132,233
122,210
105,583
91,147
96,853
72,687
208,265
210,398
196,851
166,345
140,436
125,469
111,336
100,727
85,357
72,046
61,492
47,625
35,522
22,440
22,44035,52247,62561,49272,04685,357100,727111,336125,469140,436166,345196,851210,398208,26572,68796,85391,147105,583122,210132,233113,160115,6785,9777,6134741,435-8,740-5,513-2,3167211,4651,4602,8024,6755,5747,04210,20511,76413,8368,8102,4944,593-20,722-1,109-31-28-14-21-2-201100
   Common Stock
0
0
24
0
24
24
24
29
29
29
8
44
54
54
11
11
12
12
12
12
12
12
13
13
13
13
3
13
30
31
10
10
14
15
16
16
16
17
17
18
28
29
30
29
30
30
30
30
30
30
30
30
30
33
3330303030303030303029302928181717161616151410103130133131313131212121212121111545444829292924242402400
   Retained Earnings Total Equity0000000-513,735-488,433-462,111000000-201,5300-158,553-141,651-130,5320-115,332-111,662-107,540-104,854-97,724-94,344-90,994-87,792-86,365-85,383-83,750-81,768-80,738-79,097-75,780-73,920-71,4590-76,122-82,165-79,702-85,1570-75-72-570-250000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-5
0
-1,360
-1
0
0
-3
0
0
0
0
-16
-44
-64
-83
-107
0
-2
-3
-3
-4
0
-6
-7
0
-10
-11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000-11-100-7-60-4-3-3-20-107-83-64-44-160000-300-1-1,3600-500000
   Capital Surplus 
0
0
0
0
0
0
15
15
15
0
64,388
84,240
84,604
84,921
0
85,284
85,672
85,972
86,127
86,299
86,431
86,540
86,831
87,817
88,501
88,666
88,819
88,971
106,259
107,983
119,237
121,299
235,523
243,677
273,868
280,747
0
292,661
0
0
0
0
0
0
602,517
613,872
625,041
0
0
0
0
0
0
0
0000000625,041613,872602,517000000292,6610280,747273,868243,677235,523121,299119,237107,983106,25988,97188,81988,66688,50187,81786,83186,54086,43186,29986,12785,97285,67285,284084,92184,60484,24064,3880151515000000
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
-1
15
15
15
15
54,201
64,388
84,240
84,604
84,921
85,284
85,672
85,972
86,127
86,299
86,431
86,540
86,831
87,817
88,501
88,666
88,828
88,971
106,259
107,983
119,266
121,299
235,523
243,677
273,868
280,747
284,882
292,661
324,918
343,358
513,304
555,182
581,569
590,483
602,517
613,872
625,041
636,434
646,230
654,747
661,960
669,820
676,374
680,849
680,849676,374669,820661,960654,747646,230636,434625,041613,872602,517590,483581,569555,182513,304343,358324,918292,661284,882280,747273,868243,677235,523121,299119,266107,983106,25988,97188,82888,66688,50187,81786,83186,54086,43186,29986,12785,97285,67285,28484,92184,60484,24064,38854,20115151515-100000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-30,184
Operating Income-83,891-30,184
 
Operating Expense (+$)
Research Development5,933
Selling General Administrative37,716
Selling And Marketing Expenses13,464
Operating Expense30,18457,113
 
Net Interest Income (+$)
Interest Income3,530
Interest Expense-0
Other Finance Cost-0
Net Interest Income3,530
 
Pretax Income (+$)
Operating Income-83,891
Net Interest Income3,530
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-79,979-87,803
EBIT - interestExpense = -163,870
-79,979
-79,979
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-163,870-79,979
Earnings Before Interest and Taxes (EBITDA)-79,979
 
After tax Income (+$)
Income Before Tax-79,979
Tax Provision-0
Net Income From Continuing Ops-79,979-79,979
Net Income-79,979
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses83,891
Total Other Income/Expenses Net3,912-3,530
 

Technical Analysis of Relmada
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Relmada. The general trend of Relmada is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Relmada's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Relmada Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Relmada Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.7349 < 0.9 < 1.88.

The bearish price targets are: 0.52 > 0.52 > 0.2675.

Know someone who trades $RLMD? Share this with them.πŸ‘‡

Relmada Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Relmada Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Relmada Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Relmada Therapeutics Inc. The current macd is -0.00133927.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Relmada price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Relmada. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Relmada price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Relmada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartRelmada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Relmada Therapeutics Inc. The current adx is 27.52.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Relmada shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Relmada Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Relmada Therapeutics Inc. The current sar is 0.53263784.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Relmada Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Relmada Therapeutics Inc. The current rsi is 49.64. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Relmada Therapeutics Inc Daily Relative Strength Index (RSI) ChartRelmada Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Relmada Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Relmada price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Relmada Therapeutics Inc Daily Stochastic Oscillator ChartRelmada Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Relmada Therapeutics Inc. The current cci is -52.75541877.

Relmada Therapeutics Inc Daily Commodity Channel Index (CCI) ChartRelmada Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Relmada Therapeutics Inc. The current cmo is -3.76525249.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Relmada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartRelmada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Relmada Therapeutics Inc. The current willr is -53.38983051.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Relmada is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Relmada Therapeutics Inc Daily Williams %R ChartRelmada Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Relmada Therapeutics Inc.

Relmada Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Relmada Therapeutics Inc. The current atr is 0.07777037.

Relmada Therapeutics Inc Daily Average True Range (ATR) ChartRelmada Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Relmada Therapeutics Inc. The current obv is -1,812,405.

Relmada Therapeutics Inc Daily On-Balance Volume (OBV) ChartRelmada Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Relmada Therapeutics Inc. The current mfi is 43.18.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Relmada Therapeutics Inc Daily Money Flow Index (MFI) ChartRelmada Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Relmada Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Relmada Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Relmada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.641
Ma 20Greater thanMa 500.685
Ma 50Greater thanMa 1000.586
Ma 100Greater thanMa 2000.439
OpenGreater thanClose0.620
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Relmada with someone you think should read this too:
  • Are you bullish or bearish on Relmada? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Relmada? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Relmada Therapeutics Inc

I send you an email if I find something interesting about Relmada Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Relmada Therapeutics Inc.

Receive notifications about Relmada Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.